土壤和种子:瘤微环境培养免疫疗法抵抗和更新
Yiya Li1, Qiushi Feng1, Yangyang Xia1
1Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing 100081, China.
International journal of molecular sciences
|November 13, 2025
概括
瘤微环境 (TME) 通过产生抗性来阻碍癌症免疫疗法. 针对TME的策略,包括树皮正常化和微生物群工程,有望改善治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 癌症免疫疗法,包括免疫检查点抑制剂 (ICI) 和仿真抗原受体T细胞 (CAR-T) 疗法,是关键的临床策略.
- 治疗疗效经常受到原发性和获得性耐药性的损害.
- 瘤微环境 (TME) 是免疫疗法耐药性的关键决定因素.
研究的目的:
- 系统地审查TME调解抗癌免疫疗法的多方面的机制.
- 为了比较与ICI和CAR-T疗法相关的耐药性机制.
- 讨论克服TME介导抗性的新兴策略.
主要方法:
- 对临床前和临床研究的系统文献综述.
- 在不同免疫疗法模式中对抗性机制的比较分析.
- 综合关于TME准策略的当前知识.
主要成果:
- 在TME使用不同的细胞,代谢,机械和微生物组件来诱导耐药性.
- 在ICI和CAR-T疗法中存在共享耐药机制.
- 新兴的策略重点是调节免疫微环境,肌体正常化,代谢重编程和微生物群工程.
结论:
- 了解TME介导的耐药性对于提高免疫疗法的疗效至关重要.
- 准TME为组合疗法提供了有前途的途径.
- 需要进一步的研究和临床转化,以改善癌症免疫疗法患者的治疗结果.
相关概念视频
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Stem Cells and Tumor Maintenance
5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K


